NAVB
AMEXNavidea Biopharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Latest news
25 items- PRNavidea Biopharmaceuticals, Inc. Files for BankruptcyNavidea Biopharmaceucitals, Inc. files for Bankruptcy Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company"), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the "Court") on October 1, 2025. The filing is intended to enable the Company to pursue an orderly restructuring of its financial obligations while continuing limited operations to preserve value for creditors and stakeholders. The Company intends to use the Chapter 11 pro
- PRNavidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock SplitNavidea Biopharmaceucitals, Inc. extends deadline to implement a reverse stock split Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares. The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was initially set to expire on July 8, 2025, ha
- PRNavidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax AssetsNavidea Biopharmaceuticals, Inc. ("Navidea" or the "Company") today announced that its Board of Directors has elected to extend the Company's Section 382 Rights Agreement (the "Section 382 Rights Plan"). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. The Section 382 Rights Plan is designed to safeguard Navidea's ability to utilize its net operating loss carryforwards ("NOLs") and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in R&D tax credits that may be used to offset future taxable income. However, these valuable tax attributes
- PRNavidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024Navidea Biopharmaceuticals, Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company's pivotal NAV3-33 clinical trial titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)" (ClinicalTrials.gov Identifier: NCT05246280) the "RA Trial." The purpose of the exploratory analysis was to optimize th
- PRNavidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024 Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company's certificate of incorporation to allow stockholders to act by written consent, and (ii) an amendment to the Company's certificate of incorporation to implement a reverse stock
- 13D/GSEC Form SC 13D/A filed by Navidea Biopharmaceuticals Inc. (Amendment)SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
- SECSEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- PRNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsNavidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock, preferred stock purchase rights and Series K preferred stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting oblig
- SECSEC Form S-8 POS filed by Navidea Biopharmaceuticals Inc.S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form S-8 POS filed by Navidea Biopharmaceuticals Inc.S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form S-8 POS filed by Navidea Biopharmaceuticals Inc.S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form POS AM filed by Navidea Biopharmaceuticals Inc.POS AM - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form POS AM filed by Navidea Biopharmaceuticals Inc.POS AM - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form S-8 POS filed by Navidea Biopharmaceuticals Inc.S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form S-8 POS filed by Navidea Biopharmaceuticals Inc.S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form S-8 POS filed by Navidea Biopharmaceuticals Inc.S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form POS AM filed by Navidea Biopharmaceuticals Inc.POS AM - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form S-8 POS filed by Navidea Biopharmaceuticals Inc.S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form POS AM filed by Navidea Biopharmaceuticals Inc.POS AM - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form S-8 POS filed by Navidea Biopharmaceuticals Inc.S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
- SECSEC Form POS AM filed by Navidea Biopharmaceuticals Inc.POS AM - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
NAVB FAQ
5 questionsWhat does Navidea Biopharmaceuticals Inc. do?
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or...Where does NAVB stock trade?
Navidea Biopharmaceuticals Inc. (NAVB) is listed on AMEX.What sector and industry is NAVB in?
Navidea Biopharmaceuticals Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What companies are similar to NAVB?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), NNNN (Anbio Biotechnology), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.). Compare NAVB side-by-side with any of them on Quantisnow.How can I track NAVB on Quantisnow?
Quantisnow aggregates Navidea Biopharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NAVB to receive live email and push alerts on every new disclosure.